Abstract. In human cancer, high expression of telomerase is correlated with tumor aggressiveness and metastatic potential. Human telomerase reverse transcriptase (hTERT), which regulates telomere length, can promote tumor development. Most research on hTERT has been focused on its crucial function of telomere maintenance. However, there are many phenomena that cannot be explained by its reverse transcriptase activity. Accumulating evidence suggests that hTERT has functions independent of its protective function at the telomere ends, such as increasing the anti-apoptotic capacity of cells, enhancing DNA repair, maintaining stem cells and regulating gene expression. This review will provide an update on the nonreverse transcriptase activity of hTERT and its contribution to tumor formation, metastasis and cancer stem cell maintenance. Repression of the non-reverse transcriptase activity of hTERT may be a new strategy for tumor therapy.
Introduction
Telomerase is a reverse transcriptase that carries its own template and synthesizes DNA telomere repeats to maintain telomere length. These repeats are composed of 1000-2000 non-coding tandem repeats of the TTAGGG sequence and serve as protective ʻcapsʼ at the ends of chromosomes, protecting the chromosomes from degradation and thereby maintaining chromosome stability, enhancing cell proliferation and promoting cell immortality (1) (2) (3) (4) (5) . In most cell types, after each round of DNA replication, the telomeres are shortened. However, telomere length is stabilized by the telomerase enzyme in some stem cells, and telomerase activation is a very common occurrence in tumor cells (6) (7) (8) (9) . In humans, the active telomerase is composed of two components: i) human telomerase RNA (hTR), which contains the template for reverse transcription and is expressed in most cells; and ii) human telomerase reverse transcriptase (hTERT), which is a reverse transcriptase that catalytically synthesizes telomere DNA. hTERT expression seems to be restricted to telomerase-positive tissues, which indicates that hTERT is the limiting factor for telomerase activity (10) (11) (12) (13) . Recently, evidence was shown that hTERT alone is sufficient to restore telomerase activity and this restoration results in tumorigenesis in telomerase negative cells, such as epithelial cells and human fibroblasts (14) (15) (16) . Tumors express high levels of hTERT (80-90%) (17) , suggesting that the reverse transcriptase activity of hTERT plays an important role in tumor occurrence and development.
Most research on hTERT has been focused on its crucial function of telomere maintenance. However, there are many phenomena that cannot be explained by its reverse transcriptase activity. Recent research has discovered that hTERT has other functions unrelated to its reverse transcriptase activity, such as increasing the anti-apoptotic capacity of cells, enhancing DNA repair, maintaining stem cells and regulating gene expression (18) . Non-canonical roles of hTERT have also been revealed (19) . These non-canonical roles of hTERT are
The non-reverse transcriptase activity of the human telomerase reverse transcriptase promotes tumor progression (Review) referred to as its non-reverse transcriptase activity. We review the role and mechanisms of the non-reverse transcriptase activity of hTERT in tumor progression.
hTERT non-reverse transcriptase activity and tumor formation
Cellular immortalization is recognized as a major hallmark of cancer and it is generally accepted as a necessary step in the cancer initiation process (20) . Mounting evidence suggests that telomerase plays an important role in cellular immortalization and oncogenesis. The number of telomeres determines the proliferative capacity of the cell and hTERT plays a key role in maintaining telomere length. Cellular senescence is due to telomere shortening, and immortalization strategies typically include forced expression of hTERT (21) . In a mouse model, mouse telomerase reverse transcriptase (mTert) could immortalize wild-type (WT) and Nmp4-deletion bone marrow stromal cells, causing them to exhibit sustained growth. In other mammals and in humans, expression of exogenous hTERT in bone marrow mesenchymal stem cells (MSCs) resulted in immortalization (22) (23) (24) (25) (26) . A recent study indicated that introduction of hTERT alone was sufficient for the immortalization of human mammary epithelial cells (hMECs) grown in specialized media (27) . These previous studies demonstrate that cellular immortalization is a result of hTERT extending telomere length through its reverse transcriptase activity and telomere maintenance is an important aspect of the biological process of immortalization. Nonetheless, recent data have shown that the reverse transcriptase activity of hTERT is not necessary for cell proliferation and immortalization. Stewart et al showed that ectopic expression of hTERT in the GM847 immortal cell line imparted a tumorigenic phenotype. This outcome was also observed after introduction of a mutant hTERT that was incapable of maintaining telomere length. This indicates that hTERT has an additional function that is required for tumorigenesis but does not depend on its ability to maintain telomeres (28) .
In 2004, it was shown that in a maturation-resistant acute promyelocytic leukemia (APL) cell line, overexpression of hTERT imparted protection from apoptosis induced by tumor necrosis factor (TNF) or TNF-related apoptosis-inducing ligand (TRAIL) following all-trans retinoic acid (ATRA) treatment, and this function was independent of telomerase activity on telomeres (29) . Beliveau et al found that the enhanced cell proliferation ability of HMECs after hTERT overexpression does not rely on its reverse transcriptase function, but on its ability to modulate the DNA damage response (DDR), which in turn suppresses apoptosis (30) . These findings provide a previously unknown mechanistic explanation for the observation that exogenously expressed hTERT offers growth advantages to cells without the basic functions of its enzyme activity, indicating that hTERT has growth regulatory properties independent of its role in telomere maintenance.
hTERT has also been shown to be involved in mitochondrial apoptosis induced by targeted inhibition of Bcl-2. In addition, hTERT mutants, which are catalytically and biologically inactive, showed similar behavior as the wild-type form, indicating that hTERT inhibited apoptosis regardless of its telomerase activity and its ability to lengthen telomeres (31) . hTERT has also been found to activate Wnt signaling, therefore causing target genes to promote cell proliferation and induce carcinogenesis in normal epithelia (32, 33) . Carcinogenesis was chemically induced in TERT-positive and TERT-negative mice and their risk of skin cancer was analysed. The mice with high levels of TERT expression had a significantly higher risk of skin cancer than the hTERT-negative mice, but the length of their telomeres was not changed (34) . Mukherjee et al found that the ability of the hTERT to enhance cell proliferation can be uncoupled not only from telomere elongation but also from other telomerase activities. The cellular lifespan extension was found to be due to hTERT regulating DNA damage responses (Fig. 1A ) and reducing RNA processing endoribonucleases (RMRP) (35) . hTERT can also alleviate basal cellular reactive oxygen species (ROS) levels by potentiating the cellular antioxidant defense systems, (Fig. 1B) , thus allowing cancer cells to evade death stimuli (36) .
The data presented here, together with other recent evidence underscore that there are broad biological consequences of hTERT expression aside from its essential function in telomere maintenance. The non-reverse transcriptase activity of hTERT plays a very important role in tumor formation; this effect is independent of the reverse transcriptase activity of hTERT, and telomere extension is not necessary for cell immortalization and tumor formation.
hTERT non-reverse transcriptase activity and tumor metastasis
If superior proliferation ability is the main feature of early primary tumors, then metastasis is the main feature of endstage cancer. Metastasis directly threatens the lives of cancer patients and is the cause of 90% of cancer deaths (37) . The multi-step process of tumor invasion and metastasis, referred to as the invasion-metastasis cascade, includes loss of cellular adhesion, increased motility, entry into and survival in the circulation, exit into new tissue and eventual colonization at a distant site (38, 39) . Tumor invasion and metastasis are associated with a variety of factors and processes, including: the epithelial mesenchymal transition (EMT), heterotypic contributions of stromal cells and plasticity in the invasive growth program. EMT plays a critical role in cancer metastatic progression and it has been postulated to be an absolute requirement for tumor invasion and metastasis (40) (41) (42) (43) . EMT refers to the physiological and pathological situations occurring during cell epithelial-mesenchymal transition, accompanied by cell morphology and gene expression changes. It is characterized by the loss of epithelial proteins, including E-cadherin, γ-catenin and β-catenin, and is often accompanied by the increase of mesenchymal proteins such as vimentin, fibronectin and smooth muscle actin (19, 44) .
E-cadherin expression is a marker of epithelial cells and it is an initiating factor for EMT. The downregulation, inhibition, or loss of function of E-cadherin can activate EMT. E-cadherin also helps maintain cancer cell adhesion to prevent tumor invasion and metastasis. A variety of factors have been shown to regulate E-cadherin, including somatic mutations, promoter hypermethylation, the Snail protein and the ZEB family (45).
Evidence shows that hTERT can promote the metastasis of cells and this capability may be independent of its nonreverse transcriptase activity. Upon hTERT transfection into U2OS osteosarcoma cells, a telomerase-negative cell line, the invasion and metastasis of tumor cells were increased (46) . In human esophageal squamous cell cancer, hTERT activation increased migration and invasion when compared with control cells. It has been shown that hTERT regulates the glycolytic pathway in melanoma cells, improving the energy supply state of the tumor cells thus contributing to tumor invasion and metastasis (47, 48) . Recent studies have indicated that exogenous expression of hTERT also leads to upregulation of MMP9 and RhoC and promotes the invasiveness and metastasis of HepG2 cells in vitro (49) .
hTERT promotes not only tumor formation, but also tumor metastasis. Therefore, it is possible that hTERT promotes tumor metastasis through the EMT pathway. Transfection of TERT into Xenopus caused faster embryonic limb and neuron development compared to controls, and promoting embryonic development is one of the three main functions of EMT, which also plays a central role in embryogenesis (32,40,50) . It has also been demonstrated that hTERT can affect TGF-β1-mediated β-catenin induction and nuclear accumulation, which enhances Wnt signaling pathway activation and promotes EMT (51) (Fig. 1C) . hTERT can form a complex with the brahma-related gene 1 (BRG1) and nucleostemin (NS) through upregulation of Twist to increase EMT and this complex does not directly contribute to telomere maintenance (52) (Fig. 1C) . In summary, hTERT plays a role in tumor invasion and metastasis by promoting EMT and this function is independent of its reverse transcriptase activity.
hTERT non-reverse transcriptase activity and maintenance of cancer stem cells
In recent years, the theory of cancer stem cells (CSCs) has provided a more reasonable explanation for the formation and recurrence of malignant tumor metastasis and chemotherapy resistance. CSCs are a subset of tumor cells that have the ability to self-renew and generate the diverse cells that form the tumor (53, 54) . Evidence suggests that most solid tumors are hierarchically organized and sustained by CSCs (55) . Some scholars believe that the existence of CSCs leads to the failure of cancer treatment. Therefore, studying the mechanisms of regulation of CSCs and targeting CSCs for therapy may be a promising area for finding a cure for cancer (56) . Park et al showed that transduction of hTERT, SV40 large T antigen and four transcription factors (OCT4, SOX2, MYC and KLF4) resulted in a higher frequency of human pluripotent stem (iPS) cell colony formation (57) . A study showed that human mammary progenitor cells rendered immortal using hTERT retain both self-renewal and differentiation capacity along the luminal and myoepithelial lineages (58) . It is known that EMT and CSCs have some common features, EMT generates cancer cells with stem cell-like characteristics; stem-like cells express markers associated with EMT; and the diversity and abundance of CSCs in solid tumors allows cells the ability to undergo EMT. Mainly by non-cancer stem cells, but under certain conditions non-tumor stem cells can also adopt cancer stem cell characteristics via EMT (43, (59) (60) (61) .
Because hTERT can promote EMT through its non-reverse transcriptase activity, it may contribute to CSC maintenance. CD133, a marker of CSCs, was found to be more highly expressed in hTERT-immortalized cells than in primary prostate cells. Stem cell properties were increased when SV40ER and hTERT were introduced into breast cancer cells (62, 63) . Castelo-Branco et al found that CSCs had significantly higher levels of hTERT expression than normal tissue stem cells, but Southern blot analysis revealed that CSCs had extremely short telomeres compared with the normal tissue stem cells (64) . In a gastric cancer (GC) model, hTERT has been shown to induce stem-like activity of cancer cells, and this activity is independent of its telomere-lengthening function (51) . Further research defines a complex composed of TERT, BRG1 and NS that maintains the function of CSCs, and this interaction is independent of telomerase activity (52) . Wnt signaling activity functionally designates the colon CSC population and is a marker for colon CSCs. As described previously, hTERT can activate the Wnt signaling pathway. Therefore, hTERT regulates tumor stem cell maintenance through the Wnt signaling pathway (32, 65) (Fig. 1C) . The above data demonstrate that hTERT contributes to the maintenance of CSCs through its non-reverse transcriptase activity.
hTERT non-reverse transcriptase activity and clinical application
It is known that the majority of tumor cells express high levels of hTERT and that normal somatic cells do not express hTERT. Therefore, telomerase has been considered as a tumor marker and an attractive target for anticancer therapy for many types of cancer (66) . When the hTERT promoter is replaced by an adenoviral promoter to construct cytolytic adenovirus, it can efficiently infect tumor cells and significantly inhibit the growth of hepatoma cells. Experiments in nude mice showed that this adenovirus can reduce the formation of tumor nodules by lung cancer cells, and this was associated with low liver toxicity (67) . In addition, because of the tumor-specific expression of hTERT, some researchers believe that hTERT is a tumor-associated antigen. Studies have shown that hTERT fragments act as antigens in mice, and CD8 + and CD4 + are stimulated for expansion (68,69). GV1001, which is a 16-amino acid MHC class II-restricted hTERT peptide vaccine, consists of amino acids 611-626 (EARPALLTSRLRFIPK) of the hTERT active site (70, 71) . GV1001 has shown good antitumor efficacy in patients in phase I and II clinical trials (72, 73) . In addition, a potent hTERT inhibitor 2-[(E)-3-naphthalene-2-yl-but-2-enoylamino]-benzoic acid (BIBR1532) specifically blocks the elongation of telomerase DNA, therefore resulting in cellular senescence and inhibition of proliferation (74, 75) .
Because hTERT promoter regulation very tightly controls telomerase activity, directly targeting the hTERT promoter may be an effective method for tumor therapy (76, 77) . When telomerase-positive cells were treated with an hTERT-driven prodrug-activating enzyme which could repress the hTERT promoter, the cells became apoptotic (78) (79) (80) . However, targeting hTERT has some problems: i) hTERT activity may not be detected in the whole of the tumor, therefore it may not be sensitive to targeted therapy; ii) When hTERT is inhibited, the telomere length shortens over a period of time and tumor apoptosis may have a lag; iii) Despite inhibition of hTERT reverse transcriptase activity, some tumors evade apoptosis through other mechanisms, such as using the alternative lengthening of telomeres (ALT) pathway or activating mitochondrial adaptive mechanisms (81, 82) .
Targeting the non-reverse transcriptase activity of hTERT may solve the problems noted above. First, the hTERT nonreverse transcriptase activity is unrelated to its telomerase activity, so if the cell has no telomerase activity, the hTERT non-reverse transcriptase activity can be targeted for tumor therapy. Second, because targeting the non-reverse transcriptase activity of hTERT does not shorten telomere length, there would be no lag effect. Finally, targeting the hTERT nonreverse trans criptase activity will not activate other pathways that promote tumor proliferation and metastasis. Telomerase immunotherapy is currently an area of active research focus. Therapeutic resistance is an issue to be considered, especially because of the existence of ALT mechanisms to maintain telomeres (83) . Inhibition of the non-reverse transcriptase activity of hTERT for anticancer therapy can be used as a supplement for telomerase therapy and may even completely replace it in some tumors.
Perspectives and Conclusion
Telomerase plays an important role in the maintenance, protection and stabilization of chromosomes, but these diverse roles can lead to opportunities for cancers to activate hTERT reverse transcriptase activity during tumorigenesis and escape cell senescence (84) . Most cancer cells express hTERT, underscoring the importance of efforts to understand its mechanisms of regulation, its implications for cell survival and cancer therapy resistance, and its interaction with other signaling pathways.
In recent years, studying the reverse transcriptase activity of hTERT has been a prime research area and inhibition of telomerase activity has become a popular treatment. hTERT expression provides valuable information for early tumor diagnosis, staging and prognosis. However, some studies show that hTERT has novel functions that are independent of its reverse transcriptase activity. These include inducing tumor formation, increasing cell proliferation, promoting tumor metastasis and maintaining CSCs. These new findings will allow us to better understand the function of hTERT, and its alternative functions help clarify the unexplained phenomena that are not due to its reverse transcriptase activity.
The hTERT non-reverse transcriptase activity mechanism will open up new avenues for tumor therapy. Inhibition of hTERT non-reverse transcriptase activity has the potential to be an efficient and low toxicity method of cancer treatment. However, hTERT activity and its regulatory mechanisms and pathways are complex and diverse. Therefore, we still face many problems and challenges. Research on the non-reverse transcriptase activity of hTERT is still in its early stages, and there are many unanswered questions remaining, such as how the non-reverse transcriptase activity of hTERT affects tumor occurrence, proliferation, metastasis and CSC maintenance. Its mechanisms will require further study. For example, it is unknown whether the non-reverse transcriptase activity of hTERT is involved in normal cell division and proliferation, stem cell differentiation and embryonic development. The hTERT non-reverse transcriptase activity promotes tumor development through multiple mechanisms, so the development of targeted therapy is a complex issue that merits further study.
In summary, there is mounting evidence that hTERT has different roles when it associates with different factors or is targeted to different cellular locations away from telomeres. New functions of hTERT are only beginning to be elucidated. We plan to further study the non-reverse transcriptase activity of hTERT and determine its pro-cancer development mechanism and how it can be therapeutically targeted. We hope this research would help improve the efficiency of cancer treatment, reduce drug doses to lower the cytotoxicity in normal cells and eventually lead to a cancer cure.
